Clinical Trials Browser

Phase 1 × OTHER × prexasertib × Clear all

NCT04023669 2025-02-07

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

Phase 1 Completed

Microphthalmia, Isolated, with Coloboma 5, Brain Neoplasms, Medulloblastoma, Central Nervous System Neoplasms

NCT02649764 2023-10-04

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03057145 2021-09-02

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumor

NCT03495323 2021-04-15

A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT03735446 2019-06-12

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

Phase 1 Terminated

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute